Stephen K Frankel1, Marvin I Schwarz. 1. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Denver, Colorado, USA. frankels@NJHealth.org
Abstract
PURPOSE OF REVIEW: This review aims to highlight and place in context recent advances in and insights into the natural history, diagnosis, and management of idiopathic pulmonary fibrosis (IPF). RECENT FINDINGS: Although the diagnosis of IPF remains challenging, an evolution in systems of practice and advancing technologies are steadily improving diagnostic accuracy. The identification of concomitant pulmonary hypertension as well as acute exacerbations of the underlying disease have taken on increasing importance in the natural history of IPF. Similarly, the management of IPF remains challenging, and although a number of recent trials of novel investigational agents for the treatment of IPF yielded negative results, at least one of these trials showed significant benefit suggesting progress in the treatment of this disease. SUMMARY: Although IPF remains a diagnostic and therapeutic challenge to even the most experienced of clinicians, our knowledge of the natural history of the disease, diagnostic accuracy, and therapeutic approach continue to advance.
PURPOSE OF REVIEW: This review aims to highlight and place in context recent advances in and insights into the natural history, diagnosis, and management of idiopathic pulmonary fibrosis (IPF). RECENT FINDINGS: Although the diagnosis of IPF remains challenging, an evolution in systems of practice and advancing technologies are steadily improving diagnostic accuracy. The identification of concomitant pulmonary hypertension as well as acute exacerbations of the underlying disease have taken on increasing importance in the natural history of IPF. Similarly, the management of IPF remains challenging, and although a number of recent trials of novel investigational agents for the treatment of IPF yielded negative results, at least one of these trials showed significant benefit suggesting progress in the treatment of this disease. SUMMARY: Although IPF remains a diagnostic and therapeutic challenge to even the most experienced of clinicians, our knowledge of the natural history of the disease, diagnostic accuracy, and therapeutic approach continue to advance.
Authors: Anthony J Courey; Jeffrey C Horowitz; Kevin K Kim; Timothy J Koh; Margaret L Novak; Natalya Subbotina; Mark Warnock; Bing Xue; Andrew K Cunningham; Yujing Lin; Monica P Goldklang; Richard H Simon; Daniel A Lawrence; Thomas H Sisson Journal: Blood Date: 2011-07-06 Impact factor: 22.113
Authors: John J Osterholzer; Paul J Christensen; Vibha Lama; Jeffrey C Horowitz; Noboru Hattori; Natalya Subbotina; Andrew Cunningham; Yujing Lin; Benjamin J Murdock; Roger E Morey; Michal A Olszewski; Daniel A Lawrence; Richard H Simon; Thomas H Sisson Journal: J Pathol Date: 2012-06-06 Impact factor: 7.996
Authors: Jonathan Keow; Matthew J Cecchini; Nathashi Jayawardena; Maurizio Zompatori; Mariamma G Joseph; Marco Mura Journal: Respir Res Date: 2022-06-07
Authors: Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko Journal: Eur J Pharm Biopharm Date: 2012-12-08 Impact factor: 5.571
Authors: Sameer R Oak; Lynne Murray; Athula Herath; Matthew Sleeman; Ian Anderson; Amrita D Joshi; Ana Lucia Coelho; Kevin R Flaherty; Galen B Toews; Darryl Knight; Fernando J Martinez; Cory M Hogaboam Journal: PLoS One Date: 2011-06-21 Impact factor: 3.240